Lesinurad sodium
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 510301

CAS#: 1151516-14-1 (sodium)

Description: Lesinurad, also known as RDEA594, is a selective uric acid re-absorption inhibitor (SURI) and is also a selective inhibitor of URAT1, a transporter in the kidney that regulates uric acid excretion from the body. RDEA594 has been shown to normalize the amount of uric acid excreted by gout patients previously classified as under-excretors. Lesinurad received FDA approval on December 22, 2015.


Chemical Structure

img
Lesinurad sodium
CAS# 1151516-14-1 (sodium)

Theoretical Analysis

MedKoo Cat#: 510301
Name: Lesinurad sodium
CAS#: 1151516-14-1 (sodium)
Chemical Formula: C17H13BrN3NaO2S
Exact Mass: 403.00
Molecular Weight: 426.264
Elemental Analysis: C, 47.90; H, 3.07; Br, 18.75; N, 9.86; Na, 5.39; O, 7.51; S, 7.52

Price and Availability

Size Price Availability Quantity
50mg USD 150 Ready to ship
100mg USD 250 Ready to ship
200mg USD 450 Ready to ship
500mg USD 950 Ready to ship
1g USD 1450 Ready to ship
2g USD 2450 Ready to ship
5g USD 3650 2 weeks
Bulk inquiry

Related CAS #: 1151516-14-1 (sodium)   878672-00-5 (free acid)    

Synonym: Lesinurad sodium; Lesinurad; RDEA594; RDEA 594; RDEA-594, brand name: Zurampic.

IUPAC/Chemical Name: sodium 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetate

InChi Key: FVYMVLTWIBGEMC-UHFFFAOYSA-M

InChi Code: InChI=1S/C17H14BrN3O2S.Na/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14;/h1-4,7-8,10H,5-6,9H2,(H,22,23);/q;+1/p-1

SMILES Code: O=C(O[Na])CSC1=NN=C(Br)N1C2=C3C=CC=CC3=C(C4CC4)C=C2

Appearance: solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:   Related CAS# 1151516-14-1 ( Lesinurad sodium) 878672-00-5 ( Lesinurad free acid)       

Biological target: Lesinurad sodium -is a URAT1 and OAT inhibitor, is determined to be a substrate for the kidney transporters OAT1 and OAT3 with Km values of 0.85 and 2 µM, respectively.
In vitro activity: Cells treated with lesinurad were indistinguishable from DMSO-treated cells and even undifferentiated controls (Fig. 5A). Of note, lesinurad exhibited no cytotoxicity up to 50 μM (data not shown) excluding that the lack of lipid accumulation is a toxic effect. To gain deeper understanding of lesinurad-mediated PPARγ modulation in adipocytes, this study analyzed their gene expression profiles after differentiation (Fig. 5B). Compared to DMSO-treated cells, the full PPARγ agonist rosiglitazone robustly induced the scavenger receptor CD36, adiponectin, fatty acid binding protein 4 (FABP4) and the glucose transporter 4 (GLUT4). In strong contrast, lesinurad at 30 μM caused almost no changes in PPARγ-regulated gene expression with only slight trends for CD36 and adiponectin induction. Thus, the gene expression profiles confirmed the results of the staining experiments and indicated that lesinurad does not activate pro-adipogenic PPARγ target gene transcription in adipocytes to cause lipid accumulation. In contrast, in human hepatoma cells (HepG2 cells), lesinurad caused a more distinguished effect on PPARγ-regulated genes (Fig. 5C). As in adipocytes, lesinurad hardly affected CD36 and adiponectin expression but markedly induced angiopoietin-like 4 (ANGPTL4). Reference: Sci Rep. 2018; 8: 13554. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131501/
In vivo activity: Hyperuricemic group showed an increase in serum levels of GPT, GOT, uric acid and BUN. HU group received either ALP or ZUR (Lesinurad) showed a decrease in GPT, GOT, uric acid and BUN levels (Fig. 1a-b). Co-administration of ALP and ZUR revealed an ameliorative and additive synergistic effect (P < 0.05) on the normalization of GPT, GOT, uric acid and BUN levels (Fig. 1a). It should be noted that ZUR revealed same effect induced by ALP in hyperuricemic administered mice. Reference: BMC Pharmacol Toxicol. 2020; 21: 10. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011467/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 55.5 137.97
Ethanol 85.0 199.41
Water 8.0 18.77

Preparing Stock Solutions

The following data is based on the product molecular weight 426.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Heitel P, Gellrich L, Heering J, Goebel T, Kahnt A, Proschak E, Schubert-Zsilavecz M, Merk D. Urate transporter inhibitor lesinurad is a selective peroxisome proliferator-activated receptor gamma modulator (sPPARγM) in vitro. Sci Rep. 2018 Sep 10;8(1):13554. doi: 10.1038/s41598-018-31833-4. PMID: 30202096; PMCID: PMC6131501. 2. Alghamdi YS, Soliman MM, Nassan MA. Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study. BMC Pharmacol Toxicol. 2020 Feb 10;21(1):10. doi: 10.1186/s40360-020-0386-7. PMID: 32041665; PMCID: PMC7011467.
In vitro protocol: 1. Heitel P, Gellrich L, Heering J, Goebel T, Kahnt A, Proschak E, Schubert-Zsilavecz M, Merk D. Urate transporter inhibitor lesinurad is a selective peroxisome proliferator-activated receptor gamma modulator (sPPARγM) in vitro. Sci Rep. 2018 Sep 10;8(1):13554. doi: 10.1038/s41598-018-31833-4. PMID: 30202096; PMCID: PMC6131501.
In vivo protocol: 1. Alghamdi YS, Soliman MM, Nassan MA. Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study. BMC Pharmacol Toxicol. 2020 Feb 10;21(1):10. doi: 10.1186/s40360-020-0386-7. PMID: 32041665; PMCID: PMC7011467.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK547982/ PubMed PMID: 31643315.

2: Pérez-Ruiz F, Jansen T, Tausche AK, Juárez-Campo M, Gurunath RK, Richette P. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout. Drugs Context. 2019 May 29;8:212581. doi: 10.7573/dic.212581. eCollection 2019. Review. PubMed PMID: 31191704; PubMed Central PMCID: PMC6544139.

3: Dean L. Lesinurad Therapy and CYP2C9 Genotype. 2019 Feb 11. In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK537366/ PubMed PMID: 30742400.

4: Jansen TL, Perez-Ruiz F, Tausche AK, Richette P. International position paper on the appropriate use of uricosurics with the introduction of lesinurad. Clin Rheumatol. 2018 Dec;37(12):3159-3165. doi: 10.1007/s10067-018-4306-9. Epub 2018 Sep 22. Review. PubMed PMID: 30244431.

5: Claus LW, Saseen JJ. Patient considerations in the management of gout and role of combination treatment with lesinurad. Patient Relat Outcome Meas. 2018 Jul 18;9:231-238. doi: 10.2147/PROM.S108868. eCollection 2018. Review. PubMed PMID: 30140163; PubMed Central PMCID: PMC6054769.

6: On PC. Lesinurad (Zurampic) for Gout. Am Fam Physician. 2018 Mar 15;97(6):374-375. Review. PubMed PMID: 29671542.

7: Haber SL, Fente G, Fenton SN, Walker EP, Weaver BM, Cano AJ, Vu K. Lesinurad: A Novel Agent for Management of Chronic Gout. Ann Pharmacother. 2018 Jul;52(7):690-696. doi: 10.1177/1060028018762103. Epub 2018 Feb 26. Review. PubMed PMID: 29482353.

8: Jones G, Panova E, Day R. Guideline development for the management of gout: role of combination therapy with a focus on lesinurad. Drug Des Devel Ther. 2017 Oct 24;11:3077-3081. doi: 10.2147/DDDT.S97959. eCollection 2017. Review. Erratum in: Drug Des Devel Ther. 2017 Dec 15;11:3589-3590. PubMed PMID: 29123379; PubMed Central PMCID: PMC5661481.

9: Deeks ED. Lesinurad: A Review in Hyperuricaemia of Gout. Drugs Aging. 2017 May;34(5):401-410. doi: 10.1007/s40266-017-0461-y. Review. PubMed PMID: 28425024.

10: Gupta A, Sharma PK, Misra AK, Singh S. Lesinurad: A significant advancement or just another addition to existing therapies of gout? J Pharmacol Pharmacother. 2016 Oct-Dec;7(4):155-158. doi: 10.4103/0976-500X.195897. Review. PubMed PMID: 28163535; PubMed Central PMCID: PMC5242027.

11: Lesinurad (Zurampic) for gout-associated hyperuricemia. Med Lett Drugs Ther. 2016 Nov 21;58(1508):148-150. Review. PubMed PMID: 27849193.

12: Hoy SM. Lesinurad: First Global Approval. Drugs. 2016 Mar;76(4):509-16. doi: 10.1007/s40265-016-0550-y. Review. PubMed PMID: 26861027.